Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Research article

Estimates of the duration of the early and late stage of gambiense sleeping sickness

Francesco Checchi1*, João AN Filipe2, Daniel T Haydon3, Daniel Chandramohan1 and François Chappuis45

Author affiliations

1 Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E7HT, UK

2 Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E7HT, UK

3 Division of Environmental and Evolutionary Biology, University of Glasgow, Glasgow G12 8QQ, UK

4 Médecins Sans Frontières, Swiss section, Rue de Lausanne 78, 1211 Geneva 21, Switzerland

5 Geneva University Hospitals, Travel and Migration Medicine Unit, Rue Micheli-du-Crest 24, 1211 Geneva 14, Switzerland

For all author emails, please log on.

Citation and License

BMC Infectious Diseases 2008, 8:16  doi:10.1186/1471-2334-8-16

Published: 8 February 2008

Abstract

Background

The durations of untreated stage 1 (early stage, haemo-lymphatic) and stage 2 (late stage, meningo-encephalitic) human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense are poorly quantified, but key to predicting the impact of screening on transmission. Here, we outline a method to estimate these parameters.

Methods

We first model the duration of stage 1 through survival analysis of untreated serological suspects detected during Médecins Sans Frontières interventions in Uganda and Sudan. We then deduce the duration of stage 2 based on the stage 1 to stage 2 ratio observed during active case detection in villages within the same sites.

Results

Survival in stage 1 appears to decay exponentially (daily rate = 0.0019; mean stage 1 duration = 526 days [95%CI 357 to 833]), possibly explaining past reports of abnormally long duration. Assuming epidemiological equilibrium, we estimate a similar duration of stage 2 (500 days [95%CI 345 to 769]), for a total of nearly three years in the absence of treatment.

Conclusion

Robust estimates of these basic epidemiological parameters are essential to formulating a quantitative understanding of sleeping sickness dynamics, and will facilitate the evaluation of different possible control strategies.